---
title: "ZHIFEI-BIOL: CA111 injection has received approval for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257695365.md"
description: "ZHIFEI-BIOL's subsidiary, Chen'an Biotech, has received clinical trial approval from the National Medical Products Administration for its CA111 injection, allowing trials to be conducted in overweight or obese adult patients. CA111 is a dual agonist that targets GIP and GLP-1 receptors, aimed at improving blood glucose control and weight loss through a synergistic mechanism"
datetime: "2025-09-17T09:43:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257695365.md)
  - [en](https://longbridge.com/en/news/257695365.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257695365.md)
---

# ZHIFEI-BIOL: CA111 injection has received approval for clinical trials

According to the Zhitong Finance APP, ZHIFEI-BIOL (300122.SZ) announced that its controlling subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd. (referred to as "Chen'an Biopharmaceutical"), has received the clinical trial approval notice from the National Medical Products Administration for its CA111 injection, allowing clinical trials to be conducted in adult overweight or obese patients.

The announcement stated that the CA111 injection developed by Chen'an Biopharmaceutical is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. GIP is a gastrointestinal regulatory peptide consisting of 42 amino acids, which plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β-cells and protecting pancreatic β-cells in the presence of glucose. GLP-1 is a peptide consisting of 37 amino acids that stimulates insulin secretion, protects pancreatic β-cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight. The dual receptor agonist of GIP and GLP-1 can achieve a synergistic complementary effect of both mechanisms by activating GIP and GLP-1 receptors, thereby exerting better effects on blood sugar reduction and weight loss

### Related Stocks

- [300122.CN](https://longbridge.com/en/quote/300122.CN.md)

## Related News & Research

- [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md)
- [Farnam Celebrates 80 Years of Horse Care With New Innovations and the Horse Care Grant Sweepstakes | CENT Stock News](https://longbridge.com/en/news/287053110.md)
- [Figure AI had one of its robots race a human to sort packages. It lost.](https://longbridge.com/en/news/286883540.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)